Validation of novel advanced DNA diagnostics for streamlined and cost effective analysis of genetic disorders
| Reference number | |
| Coordinator | VANADIS DIAGNOSTICS AB |
| Funding from Vinnova | SEK 3 615 363 |
| Project duration | November 2014 - May 2016 |
| Status | Completed |
Purpose and goal
The goal of the project was to support development of Vanadis smart NIPT technology, from early stage concept to clinical validation. We have successfully proven the technology on clinical samples, collected by our partner at Karolinska Hospital (behovsägaren), and the manual assay has been implemented on prototype instruments.
Results and expected effects
As a result of the successful project, PerkinElmer acquired Vanadis in December 2015. PerkinElmer is a US corporation that is the market leader in traditional prenatal diagnosis. Vanadis will now have financial back up to take the technology to commercial stage, including filing for CE-IVD. By the acquisition of Vanadis, Perkin-Elmer will get access to advanced molecular technology and a world-class team in molecular biology development
Approach and implementation
The project was focused on the work packages described in the application. The company was staffed accordingly and individual project plans for the individual WPs was generated. The main goal with the company remained intact thoughout the project, keeping the team focused on the execution.